Hyderabad-based drugmaker will license and supply 75 generic drugsthat address a $200m market to Pfizer
After trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen.
The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe.
That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.
After trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen. The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe. That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.
Mumbai-based generic drug maker Piramal Healthcare Limited has completed its previously announced acquisition of Minrad International, a provider of generic inhalation anesthetics.
It may be noted that US-based Minrad had approved the deal at the special meeting of stock holders held on February 27.
Under the arrangement, holders of Minrad common stock will receive, in exchange for their shares, cash amount of US$0.12 per share.
Manufacturer Novartis recalled 21,000 doses of the meningitis C vaccine as a precautionary step.
Novartis said that it had discovered traces of Staphylococcus Aureus in the aluminium hydroxide solvent in which the vaccine is suspended, during tests on other vials - made at the same time - which had as an experiment been sent by air, rather than by road as they were to Britain. The Staphylococcus Aureus bacterium is associated with blood poisoning and skin infections.
After trying it out for almost a year, the world's biggest drug-maker Pfizer Inc, has decided to turn copycat in right earnest. And the $50 billion giant will take the help of Hyderabad-based Aurobindo Pharma, an established copycat drug-maker, to make this happen. The multinational will license 70 generic drugs and 12 sterile injectibles, including penicillins and cephalosporins, which according to industry watchers are valued at over $200 million in sales, from Aurobindo for marketing in the US, and Europe. That is good news for Aurobindo but may not leave much for Pfizer to smile about, say analysts.
Mumbai-based generic drug maker Piramal Healthcare Limited has completed its previously announced acquisition of Minrad International, a provider of generic inhalation anesthetics. 
Manufacturer Novartis recalled 21,000 doses of the meningitis C vaccine as a precautionary step. 
